Thermo Fisher Scientific Inc. announced findings from new research by the Tufts Center for the Study of Drug Development (CSDD) demonstrating significant benefits of its Accelerator™ Drug Development 360° CDMO and CRO solutions. The study shows that Thermo Fisher’s integrated services can potentially reduce drug development timelines by up to nearly three years, or 34 months, from Phase I through Phase III.
The research highlights that streamlining drug development is crucial for biotech and biopharma companies facing high development costs and complex regulatory environments. The study found that integrated CRO/CDMO services can generate up to $63 million in net financial benefits for drug sponsors, representing a return on investment of up to 113 times the initial investment.
To date, over 120 biotech and biopharma companies have utilized Thermo Fisher’s integrated CDMO and CRO solutions across more than 350 protocols in various therapeutic areas, including small molecule, large molecule, and advanced therapies. This external validation reinforces Thermo Fisher's competitive advantage and its ability to deliver substantial value by addressing operational inefficiencies in drug development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.